Amarin Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw strong international growth for VASCEPA, especially in Europe via Recordati, and stable U.S. performance despite pricing pressure. Operating expenses dropped 59%, cash flow remained positive, and the company ended the quarter with $314.6 million in cash and no debt.
-
Q2 2024 revenue declined year-over-year due to U.S. generic competition, but international growth, especially in Europe and China, offset some pressure. Cost-saving initiatives improved profitability, and the company remains focused on global expansion and maintaining U.S. market leadership.
-
Q1 2026 saw revenue growth, improved margins, and a second consecutive quarter of positive cash flow, driven by a new operating model and strong international momentum. Vascepa maintained U.S. leadership, while updated guidelines and restructuring supported future growth.